A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
| 対象疾患 | Glioblastoma, Glioblastoma Multiforme |
|---|---|
| 相 | 第1相 |
| スポンサー | Bryan Allen |
| ステータス | 実施中（募集終了） |
| 参加者数 | 16 名 |
| 介入（薬剤） | Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide |
| 開始日 | 2023年2月28日 |
| 完了日 | 2025年5月13日 |
| 結果公開日 | 2026年7月20日 |
概要
This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)
| Cohort 1 | 2 Dose Limiting Toxicities |
|---|---|
| Cohort 2 | 0 Dose Limiting Toxicities |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed M — National Cancer Institute (NCI)